News

The chief executive officer at Elixirgen Therapeutics provided commentary on the promise of the Bobcat mRNA, and the mechanism of action for mRNA-like therapies to treat Duchenne muscular dystrophy.

Despite the overall cohort not reaching statistical significance on the primary end point, a subgroup of patients on SLS-005 without AMX0035 performed better.

With the added coverage, it paves the way for individuals facing the hurdles of migraine disease to obtain an easy-to-use nonpharmacological option for both acute and preventive migraine care.

The professor of epidemiology at Karolinska Institutet talked about findings from a comprehensive study on the correlation between obesity and accelerated progression of multiple sclerosis. [WATCH TIME: 8 minutes]

In collaboration with Robert A. Hauser, MD, MBA, the survey aims to understand the impact of tremors in patients with Parkinson disease.

The chief executive at Encephalitis International talked about results from a recent survey conducted on the misconceptions of encephalitis recognition among emergency medical professionals. [WATCH TIME: 5 minutes]

A panel of experts MS specialists provided commentary on the clinical development of these therapies, some of the specific agents within the pipeline, and how to navigate potential safety concerns.

Join us on April 8 on our LinkedIn and X pages for our #PreAANChat premeeting social chat ahead of the 2024 American Academy of Neurology Annual Meeting!

A 24-hour subcutaneous infusion of ND0612 was superior to oral immediate-release levodopa–carbidopa at increasing on time without troublesome dyskinesia and reducing off time in adults with Parkinson disease.

Revance’s daxibotulinumtoxinA-Ianm (Daxxify) is the first and only approved peptide-formulated, long-lasting neuromodulator for patients with cervical dystonia.

Here's some of what is coming soon to NeurologyLive® this week.

New findings from a phase 1 trial presented at AD/PD 2024 showed that UB-312 antibodies decrease α-synuclein levels in the cerebrospinal fluid of patients with Parkinson disease.

The Melissa and Paul Anderson President’s Distinguished Professor of Neurology, Perelman School of Medicine, University of Pennsylvania, discussed the promising avenue of BTK inhibitors for addressing progressive multiple sclerosis. [WATCH TIME: 5 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Purple Day and epilepsy awareness.

A recent analysis of a phase 2 trial showed that repeated intrathecal injections of MSC therapy led to significant reductions in serum biomarkers and improvements in neurological function for progressive MS.

Shae Datta, MD, a neurologist and headache specialist at NYU Langone Health, discussed the effects of traumatic brain injury and the need to accurately diagnose patients in a timely manner.

Neurology News Network for the week ending March 16, 2024. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 15, 2024.

Over an 18-month period, patients demonstrated significant increases in ON time with bemdaneprocel, even after stopping immunosuppressives 1 year into treatment.

The medial director of Novartis talked about findings from a real-world study assessing ofatumumab treatment for multiple sclerosis presented at the 2024 ACTRIMS Forum. [WATCH TIME: 3 minutes]

A new feature on NeurologyLive®, IJMSC Insights offers a closer look at the latest research and the people behind it from the community of the International Journal of Multiple Sclerosis Care (IJMSC) and the Consortium of Multiple Sclerosis Centers (CMSC).

The phase 2 multisite trial is expected. to include 498 patients to assess the efficacy, safety, and tolerability of Lu AG09222 as a potential migraine preventive.

The FDA recently issued revised draft guidance to assist drug companies in developing treatments for early Alzheimer disease, focusing on diagnostic criteria, clinical staging, and outcome measures.

New findings from a phase 1b/2a study showed that NodThera's NT-0796, an oral NLRP3 inflammasome inhibitor, reduced inflammatory biomarkers among patients with Parkinson disease.

The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine discussed several notable presentations and topics from the 2024 ACTRIMS Forum, highlighting advances in MS care. [WATCH TIME: 9 minutes]

Tim Siegert, PhD, chief operating officer and co-founder of Allyx Therapeutics, provided commentary on the recently announced positive phase 1b results for ALX-001, an agent in development for Alzheimer and Parkinson disease.

The president and chief executive officer of Satellos Bioscience provided insight on a new small molecule therapy, SAT-3247, in development for patients with muscular dystrophies. [WATCH TIME: 3 minutes]

Over 61.1 patient-years of treatment experience, AOC 1001 was well tolerated in patients with DM1, with nausea and headache the most commonly reported adverse events.